Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEMO: Lebrikizumab in Localized Scleroderma
2025-524435-39-00Phase 2Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in morphea comparing Lebrikizumab (Ebglyss) 250 mg with Placebo (2 arms). Primary endpoint: Primary: mLoSSI score change at 24 weeks. Planned start May 2026; status: authorised.
02
Drugs
lebrikizumab
03
Conditions
morphea
Beyond the preview
Go deeper on 2025-524435-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524435-39-00.